EMA Releases Guideline on good pharmacogenomic practice

Genomic data is becoming ever more a central part to the evaluation of drug efficiency and safety. The aim of the guidelines, which were released for public consultation on 2nd May, outline to requirements related to the choice of appropriate genomic methodologies during the development and life-cycle of a drug.

To read more about these guidelines, please click here.

Tagged with

Published on 4. May 2016 in News EU